PMID- 20693809
OWN - NLM
STAT- MEDLINE
DCOM- 20110602
LR  - 20151119
IS  - 1660-2110 (Electronic)
IS  - 1660-2110 (Linking)
VI  - 117
IP  - 2
DP  - 2011
TI  - Addition of infliximab to standard therapy for ANCA-associated vasculitis.
PG  - c89-97
LID - 10.1159/000319655 [doi]
AB  - BACKGROUND: Tumour necrosis factor-alpha (TNF) is implicated in the pathogenesis of 
      anti-neutrophil cytoplasm antibody-associated vasculitis (AAV). Current 
      immunosuppressive therapy is associated with considerable morbidity and 
      mortality. Anti-TNF antibody therapy (infliximab) may help control AAV by 
      providing more targeted immunosuppression and allow reductions in the use of 
      corticosteroids and cyclophosphamide, thereby reducing the burden of 
      immunosuppression with its associated morbidity and mortality. METHODS: 33 
      patients with active AAV participated in this cohort study. Patients were treated 
      with standard therapy (corticosteroids and cyclophosphamide with additional 
      plasma exchange in the case of life- or organ-threatening disease) or standard 
      therapy + infliximab at weeks 0, 2, 6 and 10. The primary outcome measure was 
      time to remission. Other outcome measures were adverse events, cumulative damage 
      scores and relapse, as well as biomarkers for circulating activated and 
      regulatory T cells. Follow-up was for 12 months. RESULTS: 17 patients received 
      standard therapy alone; 16 patients received additional infliximab. The addition 
      of infliximab to standard therapy did not influence remission rates, adverse 
      events, damage index scores, relapse rates or biomarker levels in this cohort 
      study. CONCLUSION: The addition of infliximab to standard therapy did not confer 
      clinical benefit for patients with active AAV.
CI  - Copyright (c) 2010 S. Karger AG, Basel.
FAU - Morgan, Matthew D
AU  - Morgan MD
AD  - Renal Immunobiology, School of Immunity and Infection, The Medical School, 
      College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 
      m.d.morgan @ bham.ac.uk
FAU - Drayson, Mark T
AU  - Drayson MT
FAU - Savage, Caroline O S
AU  - Savage CO
FAU - Harper, Lorraine
AU  - Harper L
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100806
PL  - Switzerland
TA  - Nephron Clin Pract
JT  - Nephron. Clinical practice
JID - 101159763
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Drug Combinations)
RN  - 0 (Immunosuppressive Agents)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis/*drug 
      therapy
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Cohort Studies
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Infliximab
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
EDAT- 2010/08/10 06:00
MHDA- 2011/06/03 06:00
CRDT- 2010/08/10 06:00
PHST- 2010/02/23 00:00 [received]
PHST- 2010/04/15 00:00 [accepted]
PHST- 2010/08/10 06:00 [entrez]
PHST- 2010/08/10 06:00 [pubmed]
PHST- 2011/06/03 06:00 [medline]
AID - 000319655 [pii]
AID - 10.1159/000319655 [doi]
PST - ppublish
SO  - Nephron Clin Pract. 2011;117(2):c89-97. doi: 10.1159/000319655. Epub 2010 Aug 6.